drugset / Trial / NCT00025571

Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer

NCT00025571 ↗

Phase 1 Completed Roswell Park Cancer Institute
Treatment

Summary

RATIONALE: Photodynamic therapy uses light and drugs that make tumor cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. PURPOSE: Phase I trial to study the effectiveness of photodynamic therapy with HPPH in treating patients who have non-small cell lung cancer.

Timeline

Start
2001-06
Primary completion
2002-10
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A Unknown — Intravenous

Indications